ClinicalTrials.gg
CompletedNCT00141245Updated Jan 1, 2007

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

A Phase 3 interventional study of Pregabalin in Seizure Disorder, Partial, sponsored by Pfizer. Completed at 46 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-01-01.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.

Enrollment
7th of 18
325 · median 244
Started
1998
with 1 other
Phase 3
12 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
7 of 18
Pfizer

Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 7th largest by enrollment, is one of 2 that started in 1998, is one of 12 in phase 3, and was the 1st registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing pregabalin in Epilepsies, Partial as a file.
02

Study summary

To evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.

03

Conditions studied

  • Seizure Disorder, Partial

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have met the inclusion criteria for preceding double-blind study
  • Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria

Exclusion Criteria:

  • Cannot have absence seizures
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
325 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Efficacy

07

Study locations

46 sites
  • Pfizer Investigational Site
    Deakin, Australian Capital Territory 2600, Australia
  • Pfizer Investigational Site
    Chatswood, New South Wales 2067, Australia
  • Pfizer Investigational Site
    Westmead, New South Wales 2145, Australia
  • Pfizer Investigational Site
    Maroochydore, Queensland 4558, Australia
  • Pfizer Investigational Site
    Heidelberg, VIC 3084, Australia
  • Pfizer Investigational Site
    Woodville, 5011, Australia
  • Pfizer Investigational Site
    Graz, A-8035, Austria
  • Pfizer Investigational Site
    Innsbruck, A-6020, Austria
  • Pfizer Investigational Site
    Duffel, 2570, Belgium
  • Pfizer Investigational Site
    Helsinki, 00029, Finland
  • Pfizer Investigational Site
    Turku, FIN-20521, Finland
  • Pfizer Investigational Site
    Lyon, Cedex 69694, France
  • Pfizer Investigational Site
    Paris, Cedex 75674, France
  • Pfizer Investigational Site
    Tours, Cedex 37044, France
  • Pfizer Investigational Site
    Dijon, 21000, France
  • Pfizer Investigational Site
    Paris Cedex 13, 75651, France
  • Pfizer Investigational Site
    Roubaix, 59100, France
  • Pfizer Investigational Site
    Erlangen, 91054, Germany
  • Pfizer Investigational Site
    Freiburg, 79106, Germany
  • Pfizer Investigational Site
    Goettingen, D-37075, Germany
  • Pfizer Investigational Site
    Hamburg, 22292, Germany
  • Pfizer Investigational Site
    Mainz, 55131, Germany
  • Pfizer Investigational Site
    Moenchengladbach, 41179, Germany
  • Pfizer Investigational Site
    Muenster, 48149, Germany
  • Pfizer Investigational Site
    Munich, D-81377, Germany
  • Pfizer Investigational Site
    Firenze, 50135, Italy
  • Pfizer Investigational Site
    Pavia, 27100, Italy
  • Pfizer Investigational Site
    Perugia, 06123, Italy
  • Pfizer Investigational Site
    Pisa, 56126, Italy
  • Pfizer Investigational Site
    Heemstede, 2103 SW, Netherlands
  • Pfizer Investigational Site
    Heeze, 5591 VE, Netherlands
  • Pfizer Investigational Site
    Parow, Cape Town 7505, South Africa
  • Pfizer Investigational Site
    Durban, 4052, South Africa
  • Pfizer Investigational Site
    San Sebastian, Guipuzcoa 20014, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Gerona, 17007, Spain
  • Pfizer Investigational Site
    Sevilla, 41013, Spain
  • Pfizer Investigational Site
    Goteborg, S-413 45, Sweden
  • Pfizer Investigational Site
    Lavigny, LE, CN-1775, Switzerland
  • Pfizer Investigational Site
    Tschugg, CH-3233, Switzerland
  • Pfizer Investigational Site
    Bimingham, B15 2QZ, United Kingdom
  • Pfizer Investigational Site
    Bucks, SL9 ORJ, United Kingdom
  • Pfizer Investigational Site
    Dundee, DD1 9ND, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G11 6NT, United Kingdom
  • Pfizer Investigational Site
    Liverpool, L9 1AE, United Kingdom
  • Pfizer Investigational Site
    York, Y03 7HE, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1998 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Oct 1998
Completion
Nov 2005
Last update
Jan 1, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jan 1, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00141245
Lead sponsor
Pfizer
First posted
Sep 1, 2005
Start date
Oct 1998
Completion
Nov 2005
Last update
Jan 1, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion